All In Biotech

Free tool

FAERS Monitor: Khapzory

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211226 or its brand name (Khapzory, Levoleucovorin). Reports on generic versions are filed under their own applications.

Reports

757

Serious

737

97% of reports

Hospitalization

211

Death reported

44

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • neutropenia125
  • thrombocytopenia78
  • asthenia76
  • off label use75
  • diarrhoea64
  • nausea60
  • azotaemia59
  • anaemia37
  • vomiting35
  • pyrexia30
  • febrile neutropenia28
  • neuropathy peripheral23
  • hyperbilirubinaemia21
  • constipation20
  • leukopenia20

Reports by year received

View as table
YearReports
20092
20128
20144
20153
20162
20173
201871
201955
202019
202129
202255
2023161
2024140
2025139
202666

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,402 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
azotaemiaSignal59416.6325.423,696
hyperbilirubinaemiaSignal2156.437.01,087
neutropeniaSignal12525.621.82,942
thrombocytopeniaSignal7819.415.71,349
febrile neutropeniaSignal2811.78.2265
leukopeniaSignal2011.17.2174
neuropathy peripheralSignal236.74.5107
astheniaSignal765.64.5289
anaemiaSignal375.43.9129
diarrhoeaSignal642.82.272
constipationSignal202.51.717
pyrexiaSignal302.41.724
off label useSignal752.41.961
nauseaSignal602.11.735
vomitingSignal352.11.519

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.